Chemotherapy-Induced Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chemotherapy-induced peripheral neuropathy markets are expected to exhibit a CAGR of 4.44% during 2024-2034.
The chemotherapy-induced peripheral neuropathy market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced peripheral neuropathy (CIPN) is a distressing and often debilitating side effect that can arise as a result of certain cancer treatments. It is characterized by damage to the peripheral nerves, leading to a range of symptoms that significantly impact patients' quality of life. Common indications include tingling, numbness, burning sensations, and weakness in the extremities, particularly in the hands and feet. Individuals suffering from the illness may also experience trouble with coordination, balance, and fine motor skills. The diagnosis of CIPN involves a comprehensive assessment of the patient's medical history, including details of the chemotherapy agents used, dosage, and duration of treatment. The healthcare professional may also conduct clinical examinations, nerve conduction studies, and electromyography to evaluate nerve function and pinpoint the extent of nerve damage. Additionally, patients' self-reported symptoms play a crucial role in diagnosis. It is crucial for physicians to distinguish CIPN from various other potential causes of neuropathy and to tailor treatment strategies accordingly.
The increasing cases of cancer, which requires chemotherapy, causing damage to the nerves by interfering with their structure and function, are primarily driving the chemotherapy-induced peripheral neuropathy market. In addition to this, the inflating utilization of efficacious interventions, including neuroprotective agents, antioxidants, and nerve growth factor modulators, to effectively mitigate and alleviate the symptoms associated with CIPN is also creating a positive outlook for the market. Moreover, the widespread adoption of physical therapies and lifestyle modifications, as they aid in enhancing nerve function, minimizing discomfort, and ameliorating patients' overall quality of life, is further bolstering the market growth. Apart from this, the rising usage of novel treatments, such as scrambler therapy and dorsal root ganglion stimulation, which target neural pathways and provide relief from neuropathic pain in individuals suffering from the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of complementary therapies like acupuncture and transcutaneous electrical nerve stimulation to enhance treatment outcomes is also augmenting the market growth. Furthermore, the escalating application of regenerative medicine approaches, encompassing stem cell therapy and gene therapy, to address the root causes of CIPN by rejuvenating damaged nerve tissue and rectifying the genetic anomalies responsible for its onset is expected to drive the chemotherapy-induced peripheral neuropathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced peripheral neuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chemotherapy-induced peripheral neuropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced peripheral neuropathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chemotherapy-induced peripheral neuropathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chemotherapy-induced peripheral neuropathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chemotherapy-induced peripheral neuropathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chemotherapy-induced peripheral neuropathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chemotherapy-induced peripheral neuropathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chemotherapy-induced peripheral neuropathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chemotherapy-induced peripheral neuropathy across the seven major markets?
What is the size of the chemotherapy-induced peripheral neuropathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chemotherapy-induced peripheral neuropathy?
What will be the growth rate of patients across the seven major markets?
Chemotherapy-Induced Peripheral Neuropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chemotherapy-induced peripheral neuropathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced peripheral neuropathy market?
What are the key regulatory events related to the chemotherapy-induced peripheral neuropathy market?
What is the structure of clinical trial landscape by status related to the chemotherapy-induced peripheral neuropathy market?
What is the structure of clinical trial landscape by phase related to the chemotherapy-induced peripheral neuropathy market?
What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced peripheral neuropathy market?
The chemotherapy-induced peripheral neuropathy market has been comprehensively analyzed in IMARC's new report titled "Chemotherapy-Induced Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chemotherapy-induced peripheral neuropathy (CIPN) is a distressing and often debilitating side effect that can arise as a result of certain cancer treatments. It is characterized by damage to the peripheral nerves, leading to a range of symptoms that significantly impact patients' quality of life. Common indications include tingling, numbness, burning sensations, and weakness in the extremities, particularly in the hands and feet. Individuals suffering from the illness may also experience trouble with coordination, balance, and fine motor skills. The diagnosis of CIPN involves a comprehensive assessment of the patient's medical history, including details of the chemotherapy agents used, dosage, and duration of treatment. The healthcare professional may also conduct clinical examinations, nerve conduction studies, and electromyography to evaluate nerve function and pinpoint the extent of nerve damage. Additionally, patients' self-reported symptoms play a crucial role in diagnosis. It is crucial for physicians to distinguish CIPN from various other potential causes of neuropathy and to tailor treatment strategies accordingly.
The increasing cases of cancer, which requires chemotherapy, causing damage to the nerves by interfering with their structure and function, are primarily driving the chemotherapy-induced peripheral neuropathy market. In addition to this, the inflating utilization of efficacious interventions, including neuroprotective agents, antioxidants, and nerve growth factor modulators, to effectively mitigate and alleviate the symptoms associated with CIPN is also creating a positive outlook for the market. Moreover, the widespread adoption of physical therapies and lifestyle modifications, as they aid in enhancing nerve function, minimizing discomfort, and ameliorating patients' overall quality of life, is further bolstering the market growth. Apart from this, the rising usage of novel treatments, such as scrambler therapy and dorsal root ganglion stimulation, which target neural pathways and provide relief from neuropathic pain in individuals suffering from the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of complementary therapies like acupuncture and transcutaneous electrical nerve stimulation to enhance treatment outcomes is also augmenting the market growth. Furthermore, the escalating application of regenerative medicine approaches, encompassing stem cell therapy and gene therapy, to address the root causes of CIPN by rejuvenating damaged nerve tissue and rectifying the genetic anomalies responsible for its onset is expected to drive the chemotherapy-induced peripheral neuropathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the chemotherapy-induced peripheral neuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chemotherapy-induced peripheral neuropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chemotherapy-induced peripheral neuropathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chemotherapy-induced peripheral neuropathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chemotherapy-induced peripheral neuropathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chemotherapy-induced peripheral neuropathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chemotherapy-induced peripheral neuropathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chemotherapy-induced peripheral neuropathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chemotherapy-induced peripheral neuropathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chemotherapy-induced peripheral neuropathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chemotherapy-induced peripheral neuropathy across the seven major markets?
What is the size of the chemotherapy-induced peripheral neuropathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chemotherapy-induced peripheral neuropathy?
What will be the growth rate of patients across the seven major markets?
Chemotherapy-Induced Peripheral Neuropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chemotherapy-induced peripheral neuropathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chemotherapy-induced peripheral neuropathy market?
What are the key regulatory events related to the chemotherapy-induced peripheral neuropathy market?
What is the structure of clinical trial landscape by status related to the chemotherapy-induced peripheral neuropathy market?
What is the structure of clinical trial landscape by phase related to the chemotherapy-induced peripheral neuropathy market?
What is the structure of clinical trial landscape by route of administration related to the chemotherapy-induced peripheral neuropathy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - UNMET NEEDS
10 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - KEY ENDPOINTS OF TREATMENT
11 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - MARKETED PRODUCTS
11.1 List of Chemotherapy-Induced Peripheral Neuropathy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - PIPELINE DRUGS
12.1 List of Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Across the Top 7 Markets
12.1.1 WST-057 - WinSanTor
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ATX01 - AlgoTherapeutix
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Tetrodotoxin - Wex Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 BXQ-350 - Bexion Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
16 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - UNMET NEEDS
10 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - KEY ENDPOINTS OF TREATMENT
11 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - MARKETED PRODUCTS
11.1 List of Chemotherapy-Induced Peripheral Neuropathy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - PIPELINE DRUGS
12.1 List of Chemotherapy-Induced Peripheral Neuropathy Pipeline Drugs Across the Top 7 Markets
12.1.1 WST-057 - WinSanTor
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ATX01 - AlgoTherapeutix
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Tetrodotoxin - Wex Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 BXQ-350 - Bexion Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chemotherapy-Induced Peripheral Neuropathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chemotherapy-Induced Peripheral Neuropathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chemotherapy-Induced Peripheral Neuropathy - Access and Reimbursement Overview
16 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
